undamentalytics Newsletter
Sign in

Niagen Bioscience, Inc. cash flow statement

In fiscal 2025, Niagen Bioscience, Inc.'s operations generated $13.5m of cash; it spent $0 on capital projects, leaving free cash flow of $13.5m. It returned $251,000 through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jan 20112011Dec 20112012Dec 20122013Dec 20132014Jan 20152015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−3−4−10−4−3−2−3−10−21−20−11−24−15712146
Depreciation and amortisation00000001111111111
Stock-based pay13313215677665467
Capital spending00000121110000000
Free cash flow−3−4−10−4−3−3−4−11−22−21−11−24−15712146
Free cash flow after stock pay−4−7−13−5−6−5−6−16−29−28−18−30−21287−1
Share buybacks——−0————00—————00—
Shares issued3—103026470752780———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NAGE vs ZVRANAGE vs NAIIHRTX vs NAGEETON vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Niagen Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Niagen Bioscience, Inc.